SIMBRINZA® Suspension reduced IOP in clinical trials as monotherapy1,2

Up to nearly 9 mm Hg mean IOP reduction from baseline at month 3 as monotherapy1,2


SIMBRINZA® Suspension provides 24-hour IOP-lowering coverage3

Established through an 8 AM time point

Up to nearly 35% mean IOP reduction from baseline at month 3 as monotherapy1,2


STUDY DESIGN1-3

Intent-to-treat data from two 3-month clinical studies (N=649; N=679). Patients with ocular hypertension or open-angle glaucoma with elevated IOP were given SIMBRINZA® Suspension 3 times a day (tid); brinzolamide ophthalmic suspension, 1%, 3 times a day (tid); or brimonidine tartrate ophthalmic solution, 0.2%, 3 times a day (tid). Patients’ mean IOPs at baseline were 21 to 36 mm Hg. Dosing times were at 8 AM, 3 PM, and 10 PM. For study 1 at baseline: SIMBRINZA® Suspension, n=209; brinzolamide, n=224; brimonidine, n=216. For study 2 at baseline: SIMBRINZA® Suspension, n=218; brinzolamide, n=229; brimonidine, n=232. Study 1 compared the IOP-lowering efficacy of SIMBRINZA® Suspension with the efficacy of its components brinzolamide and brimonidine. Primary end point for study 1 was the mean IOP at the 3-month visit at all time points: 8 AM, 10 AM, 3 PM, and 5 PM. Study 2 assessed the superiority of the IOP-lowering efficacy of SIMBRINZA® Suspension vs brinzolamide alone and brimonidine alone. Primary end point for study 2 was the mean IOP at 3 months at all time points: 8 AM, 10 AM, 3 PM, and 5 PM.

References: 1. Katz G, DuBiner H, Samples J, Void S, Sall K. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%. JAMA Ophthalmol. 2013;131(6):724-730. doi:10.1001/jamaophthalmol.2013.188. 2. Nguyen QH, McMenemy MG, Realini T, Whitson JT, Goode SM. Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%. J Ocul Pharmacol Ther. 2013;29(3):290-297. 3. SIMBRINZA® Suspension [prescribing information]. Fort Worth, TX: Alcon Laboratories Inc; 2015.